Full Suite of Cxbladder Tests Adopted by NZ Public Healthcare Provider Capital & Coast DHB
08th November 2018
Cancer diagnostics company, Pacific Edge (NZX: PEB), has entered into an agreement with one of New Zealand’s largest public healthcare providers, Capital & Coast District Health Board (CCDHB), to provide its suite of Cxbladder cancer diagnostic tests for the detection, management and monitoring of bladder cancer patients. Read More
Cxbladder Commercial Evaluation by Johns Hopkins Medicine
15th October 2018
Cancer diagnostics company, Pacific Edge, advises that Johns Hopkins Medicine has commenced their commercial evaluation of Cxbladder, the company’s non-invasive molecular diagnostic test for the detection and management of bladder cancer, with a number of urologists at the institution. Read More
Pacific Edge Receives Notification of Cxbladder National CMS Reimbursement Rate in the USA
12th October 2018
Cancer diagnostics company Pacific Edge (NZX: PEB) is pleased to advise that the preliminary national CMS reimbursement rate of US$760 (NZ$1,166) has been publicly notified. The national reimbursement rate covers the Cxbladder tests awarded national CPT codes in the USA earlier this year. Read More
Another Of New Zealand’s Public Healthcare Providers, Hauora Tairawhiti, Adopts Cxbladder
16th August 2018
Gisborne’s Hauora Tairāwhiti (Tairāwhiti District Health Board) to Implement Cxbladder Testing for Urology Referrals Read More
Another New Zealand Public Healthcare Provider Signs Up to Cxbladder
14th August 2018
Cancer diagnostics company Pacific Edge (NZX: PEB) has received notification from Counties Manukau District Health Board (CMDHB) regarding adoption of the suite of Cxbladder cancer diagnostic tests for use across the clinical pathway. Read More
Pacific Edge Signs First Commercial Agreement in Singapore
01st February 2018
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. Read More